Savara (SVRA) Interest Expenses (2011 - 2018)
Savara (SVRA) posted quarterly Interest Expenses of $617000.0 for Q1 2026, down 53.43% year-over-year from $1.3 million in Q1 2025, and up 126.04% quarter-over-quarter from -$2.4 million in Q4 2025.
Powered by 
Analysis
Savara (SVRA) Interest Expenses (2011 - 2018) Analysis & Trends
Savara (SVRA) has reported Interest Expenses for 16 consecutive years, with $617000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 53.43% year-over-year to $617000.0; the TTM figure through Mar 2026 stood at $78000.0 (down 97.31% YoY), while the FY2025 annual figure was $142.7 million, up 32.95% from the prior year.
- Interest Expenses rose to $617000.0 in Q1 2026 per SVRA's latest filing, from -$2.4 million in the prior quarter.
- Across five years, Interest Expenses topped out at $1.3 million in Q1 2025 and bottomed at -$2.4 million in Q4 2025.
- Historically, Interest Expenses has averaged $312812.5 across 5 years, with a median of $474000.0 in 2022.
- Annual changes were most pronounced in 2022 — Interest Expenses surged 411.11% — and 2025, when it plunged 569.11%.
- Savara's Interest Expenses stood at $428000.0 in 2022, then climbed by 25.23% to $536000.0 in 2023, then fell by 5.78% to $505000.0 in 2024, then slumped by 569.11% to -$2.4 million in 2025, then soared by 126.04% to $617000.0 in 2026.
- Business Quant data shows SVRA's Interest Expenses at $617000.0 in Q1 2026, -$2.4 million in Q4 2025, and $32000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Savara | 1.36 Bn | 1.36 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2018 | 113,000.00 |
| Mar 31, 2018 | 104,000.00 |
| Dec 31, 2017 | 123,000.00 |
| Sep 30, 2017 | 277,000.00 |
| Jun 30, 2017 | 516,000.00 |
| Mar 31, 2017 | 245,000.00 |
| Dec 31, 2016 | 245,000.00 |
| Sep 30, 2016 | 190,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Mar 31, 2016 | 519,000.00 |
| Dec 31, 2015 | 2.48 Mn |
| Sep 30, 2015 | 101,000.00 |
| Jun 30, 2015 | 1,000.00 |
| Mar 31, 2012 | 10,710.00 |
| Dec 31, 2011 | 10,738.00 |
| Sep 30, 2011 | 272.00 |